Pal-ing, Jeneva M.
HRN: 26-79-59 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/30/2025
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
03/30/2025
04/07/2025
IV
500 G
Q48
Hap
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes